*Patients who were treated only with ALG.

†Probability of developing all hematological complications (PNH, MDS/AML).

‡Frequency based on 209 patients who are long-term survivors; MDS, n = 11 (5 of which subsequently evolved to acute leukemia); acute leukemia, n = 1.

§Patients treated with IST; MDS, n = 19; AML, n = 15.

¶Two of these patients had concurrent MDS.